推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white
溶解度
DMSO: ≥20 mg/mL
起源
Abbott
SMILES 字串
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O
InChI
1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
InChI 密鑰
VXFJYXUZANRPDJ-WTNASJBWSA-N
基因資訊
human ... ACE(1636)
尋找類似的產品？ 前往 產品比較指南
應用
Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).
生化／生理作用
Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
特點和優勢
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.
訊號詞
Danger
危險聲明
危險分類
Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Christian Lewinter et al.
European journal of heart failure, 13(12), 1349-1354 (2011-10-27)
Patients with acute myocardial infarction (MI) with bundle branch block (BBB) have a poor prognosis, but distinction between left (L)- and right (R)-sided BBB is seldom made in epidemiological studies. We studied long-term mortality associated with RBBB and LBBB in
Anthony A Bavry et al.
The American journal of medicine, 124(7), 614-620 (2011-05-21)
There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary
M Dendeni et al.
International journal of pharmaceutics, 438(1-2), 61-70 (2012-09-11)
Various regulatory authorities like International Conference on Harmonization (ICH), US Food and Drug Administration, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in active pharmaceutical drugs. Qualification of the impurities is the
Michelle L O'Donoghue et al.
Clinical chemistry, 57(9), 1311-1317 (2011-07-26)
Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE
Piero Ruggenenti et al.
Journal of the American Society of Nephrology : JASN, 23(10), 1717-1724 (2012-09-01)
Micro- or macroalbuminuria is associated with increased cardiovascular risk factors among patients with type 2 diabetes, but whether albuminuria within the normal range predicts long-term cardiovascular risk is unknown. We evaluated the relationships between albuminuria and cardiovascular events in 1208
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務